Market Cap 2.21B
Revenue (ttm) 528.30M
Net Income (ttm) -56.11M
EPS (ttm) N/A
PE Ratio 115.17
Forward PE 28.20
Profit Margin -10.62%
Debt to Equity Ratio 2.01
Volume 3,683,900
Avg Vol 3,193,218
Day's Range N/A - N/A
Shares Out 307.24M
Stochastic %K 97%
Beta 0.79
Analysts Strong Sell
Price Target $17.20

Latest News on FOLD

3 Oversold Biotech Names

Jan 13, 2025, 12:56 PM EST - 3 months ago

3 Oversold Biotech Names

AVDL JAZZ VKTX XBI


Amicus Therapeutics: Cheap Heading Into 2025

Dec 27, 2024, 1:33 PM EST - 4 months ago

Amicus Therapeutics: Cheap Heading Into 2025


3 Attractive Biotechs With Recent Positives

Oct 21, 2024, 4:17 PM EDT - 6 months ago

3 Attractive Biotechs With Recent Positives

EXEL MRK TEVA XBI


Amicus: Teva Settlement Clears Revenue Path Forward For Galafold

Oct 18, 2024, 3:47 PM EDT - 6 months ago

Amicus: Teva Settlement Clears Revenue Path Forward For Galafold


'Boring' Amicus Therapeutics Is Making Progress

Sep 29, 2024, 2:44 AM EDT - 7 months ago

'Boring' Amicus Therapeutics Is Making Progress


3 'Repeatable' Biotech Trades

Sep 25, 2024, 12:46 PM EDT - 7 months ago

3 'Repeatable' Biotech Trades

DVAX GSK NTLA XBI